Drug Profile
ATTCK 20
Alternative Names: Antibody-coupled T-cell receptor anti-CD20 immunotherapy - Cogent Biosciences; ATTCK20; mRNA ACTR T-cells + rituximabLatest Information Update: 08 Oct 2020
Price :
$50
*
At a glance
- Originator Unum Therapeutics
- Developer Cogent Biosciences; National University Hospital (Singapore); Singapore General Hospital
- Class Immunotherapies; Monoclonal antibodies; T lymphocyte cell therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; B cell inhibitors; CD20 antigen inhibitors; Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 05 Oct 2020 Unum Therapeutics is now called Cogent Biosciences
- 06 Dec 2018 Unum Therapeutics has patent protection for ACTR technology in USA
- 28 Jul 2018 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Second-line therapy or greater) in Singapore (Parenteral)